1,259 results on '"Hida T"'
Search Results
152. 419O Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) – results from ASCEND-2 and ASCEND-3
153. LBA52 - Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
154. LBA61 - Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
155. 1452P - Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
156. 1455P - Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC
157. The fine structural organization of the locus coeruleus in the rat with reference to noradrenaline contents
158. Stochastic systems: The mathematics of filtering and identification and applications: Michiel Hazewinkel and Jan C. Willems (eds.) D. Reidel, Dordrecht, 1981, xii + 663 pp., $69.50 (approx.), Dfl. 160
159. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment
160. Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye
161. A refined experimental model for proliferative vitreoretinopathy
162. Dirichlet forms and white noise analysis
163. Generalized Brownian functionals and stochastic integrals
164. 415O - Prevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer
165. Light compensation points in shade-grown seedlings of deciduous broadleaf tree species with different successional traits raised under elevated CO2
166. 521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
167. 3069 Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients
168. 3068 Impact of total lesion glycolysis at pretreatment FDG PET/CT on response duration of EGFR-TKIs in advanced NSCLC harboring EGFR mutation
169. Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC
170. 1379TiP - Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor
171. 1350P - Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)
172. 1349P - Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7
173. 1348P - Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
174. 1292P - Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study
175. 89PD - Results from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs docetaxel in patients (pts) with advanced NSCLC
176. 1994 - Phase 2 study of lenvatinib in patients with RET fusion-positive adenocarcinoma of the lung
177. Brownian Motion
178. WHITE NOISE ANALYSIS AND APPLICATIONS
179. Generalized brownian functionals
180. Energy forms and white noise analysis
181. Anti-Tumor Activity of Alectinib in Crizotinib Pre-Treated Alk-Rearranged Nsclc in Jp28927 Study
182. Imaging Characteristics Associated with Driver Mutations in Patients with Non-Small-Cell Lung Cancer
183. Trans-Tenon’s retrobulbar triamcinolone infusion for the treatment of uveitis
184. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade
185. Time to first cigarette and lung cancer risk in Japan
186. Additional Analysis of WJTOG0105 Comparing Second and Third-Generation Regimens with TRT in Unresectable Stage III NSCLC
187. Crizotinib vs. Pemetrexed or Docetaxel in Advanced Alk+ Non-Small Cell Lung Cancer: Subgroup Analysis in Profile 1007
188. Effect of height of superstructure supported by shallow foundation on seismic response
189. Evaluation of pile damage in liquefiable soil based on centrifuge tests
190. LBA44_PR - Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
191. 1204PD - Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
192. Light compensation points in shade-grown seedlings of deciduous broadleaf tree species with different successional traits raised under elevated CO2.
193. Light compensation points in shade-grown seedlings of deciduous broadleaf tree species with different successional traits raised under elevated CO2.
194. Intersection local times as generalized white noise functionals
195. Japanese pyrophyllite: occurrences and applications.
196. Japanese pyrophyllite: occurrences and applications.
197. A Phase III Study Comparing Amrubicin and Cisplatin (AP) with Irinotecan and Cisplatin (IP) for the Treatment of Extended-Stage Small Cell Lung Cancer (ED-SCLC): JCOG0509
198. Randomized Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (EP/AHTRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (LD-SCLC): JCOG0202
199. Phase III Study Comparing Second- and Third-Generation Regimens with Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: An Additional Analysis by the Histological Type in the WJTOG0105 Study
200. A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.